Name: UMIN ID:
Unique ID issued by UMIN | UMIN000000843 |
---|---|
Receipt number | R000000989 |
Scientific Title | A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in breast cancer with pathologic residual tumors after preoperative chemotherapy(JBCRG-04) |
Date of disclosure of the study information | 2007/11/01 |
Last modified on | 2021/08/27 13:43:48 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2007/10/06 14:48:55 | ||
2 | Update | 2008/12/19 18:48:05 | Homepage URL Email1 |
|
3 | Update | 2008/12/19 18:48:36 | Key inclusion criteria |
|
4 | Update | 2009/10/29 19:55:28 | Recruitment status |
|
5 | Update | 2009/11/16 15:36:35 | UMIN ID1 |
|
6 | Update | 2009/11/18 11:47:56 | Public title Public title |
|
7 | Update | 2012/05/16 14:16:22 | Address Name of person sending information Division name Address Address Post marketing survey by drug manufacture etc., specified by Japanese law. Institutions |
|
8 | Update | 2012/06/26 11:43:22 | Recruitment status |
|
9 | Update | 2013/06/17 16:12:11 | Acronym Acronym |
|
10 | Update | 2014/05/12 14:11:35 | Division name TEL Last name of contact person Last name of contact person Division name Division name |
|
11 | Update | 2014/05/12 14:11:59 | Publication of results |
|
12 | Update | 2014/05/12 14:14:35 | Key secondary outcomes Key secondary outcomes |
|
13 | Update | 2014/11/07 10:29:12 | Address Address TEL Address1 Tel1 Institutions |
|
14 | Update | 2014/11/07 10:31:22 | Last follow-up date |
|
15 | Update | 2016/04/01 19:34:12 | Name of primary person or sponsor Organization Institutions |
|
16 | Update | 2016/06/13 09:29:19 | Organization Organization |
|
17 | Update | 2016/06/15 15:32:17 | Public title Public title |
|
18 | Update | 2016/06/15 15:37:40 | Narrative objectives1 |
|
19 | Update | 2016/06/15 16:05:18 | Key inclusion criteria Key inclusion criteria |
|
20 | Update | 2016/06/20 10:42:32 | Key inclusion criteria Key exclusion criteria |
|
21 | Update | 2016/06/20 13:35:40 | Key inclusion criteria Key exclusion criteria |
|
22 | Update | 2016/06/21 10:33:56 | Institutions |
|
23 | Update | 2016/07/20 11:35:09 | Institute Institute |
|
24 | Update | 2017/01/11 14:45:57 | Key inclusion criteria Key inclusion criteria |
|
25 | Update | 2017/01/11 15:04:57 | Nationality of Funding Organization Nationality of Funding Organization |
|
26 | Update | 2017/01/20 17:16:50 | Anticipated trial start date |
|
27 | Update | 2017/01/20 17:23:08 | Institutions |
|
28 | Update | 2018/08/23 15:01:51 | Recruitment status Last follow-up date Publication of results |
|
29 | Update | 2019/11/21 16:26:29 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Last name of contact person Last name of contact person Organization Division name Zip code Address Address Homepage URL Organization1 Organization Organization Address Address Tel |
|
30 | Update | 2019/11/21 16:29:17 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled |
|
31 | Update | 2019/11/21 16:49:30 | Recruitment status Date of IRB Last follow-up date |
|
32 | Update | 2021/08/13 16:40:07 | URL releasing protocol URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Date of the first journal publication of results Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
33 | Update | 2021/08/27 13:43:48 | Last name of contact person Last name of contact person |